Product Description
Palmitoyl ethanolamide is an N-(long-chain-acyl)ethanolamine that is the ethanolamide of palmitic (hexadecanoic) acid. It has a role as an anti-inflammatory drug, an antihypertensive agent, a neuroprotective agent and an anticonvulsant. It is a N-(long-chain-acyl)ethanolamine, an endocannabinoid and a N-(saturated fatty acyl)ethanolamine. It derives from a hexadecanoic acid.
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Australia | Chile | India
Approved Indications: None
Known Adverse Events: None
Company: RDC Global
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Dermatitis, Atopic|Migraine Disorders|Rhinitis, Allergic
Phase 2: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| LEVESS | P2 |
Not yet recruiting |
Healthy Volunteers |
2027-01-01 |
|
| MIGLEV-21 | P3 |
Completed |
Migraine Disorders |
2023-03-09 |
95% |
| PEA-XMA-20 | P3 |
Completed |
Dermatitis, Atopic |
2022-06-03 |
86% |
| ACTRN12619001368123 | P3 |
Completed |
Rhinitis, Allergic |
2022-01-12 |